Oppenheimer Lowers CymaBay Therapeutics (NASDAQ:CBAY) Price Target to $10.00

CymaBay Therapeutics (NASDAQ:CBAYGet Rating) had its target price reduced by equities researchers at Oppenheimer to $10.00 in a note issued to investors on Thursday, Stock Target Advisor reports. Oppenheimer’s price objective points to a potential upside of 197.62% from the company’s previous close. Oppenheimer also issued estimates for CymaBay Therapeutics’ Q4 2022 earnings at ($0.33) EPS, FY2022 earnings at ($1.50) EPS, FY2023 earnings at ($1.28) EPS, FY2024 earnings at ($0.68) EPS, FY2025 earnings at $0.04 EPS and FY2026 earnings at $0.61 EPS.

Separately, StockNews.com assumed coverage on shares of CymaBay Therapeutics in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. One investment analyst has rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.

CymaBay Therapeutics Price Performance

Shares of CymaBay Therapeutics stock opened at $3.36 on Thursday. The firm has a fifty day simple moving average of $3.49 and a 200-day simple moving average of $3.10. The company has a current ratio of 12.20, a quick ratio of 13.27 and a debt-to-equity ratio of 1.43. CymaBay Therapeutics has a 1-year low of $1.67 and a 1-year high of $4.30. The stock has a market capitalization of $284.52 million, a price-to-earnings ratio of -2.69 and a beta of 0.54.

Hedge Funds Weigh In On CymaBay Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank acquired a new stake in CymaBay Therapeutics during the 1st quarter valued at $26,000. Royal Bank of Canada grew its holdings in shares of CymaBay Therapeutics by 506.5% during the third quarter. Royal Bank of Canada now owns 7,581 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 6,331 shares during the last quarter. LVM Capital Management Ltd. MI bought a new stake in shares of CymaBay Therapeutics during the second quarter worth about $30,000. Great Lakes Advisors LLC acquired a new position in shares of CymaBay Therapeutics in the first quarter worth approximately $31,000. Finally, Jane Street Group LLC acquired a new position in CymaBay Therapeutics in the second quarter valued at approximately $36,000. 74.92% of the stock is owned by institutional investors.

About CymaBay Therapeutics

(Get Rating)

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis.

Further Reading

Stock Target Advisor logo

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.